Abstract
A baseline conjunctival provocation test (CPT) score was optimized to predict which subjects with grass pollen induced seasonal allergic rhinitis/rhinoconjunctivitis would benefit most from treatment with a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system. A corresponding predictive treatment effect of the Immunoglobulin (Ig)G4 response would further strengthen these findings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have